Pages that link to "Q26777394"
Jump to navigation
Jump to search
The following pages link to Novel immunotherapies in lymphoid malignancies (Q26777394):
Displaying 50 items.
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints (Q26745842) (← links)
- High-content molecular profiling of T-cell therapy in oncology (Q28066792) (← links)
- Targeting the TAM Receptors in Leukemia (Q28078654) (← links)
- New Therapeutic Strategies in Acute Lymphocytic Leukemia (Q30252776) (← links)
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy (Q33561644) (← links)
- Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? (Q33622342) (← links)
- HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? (Q33632104) (← links)
- Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies (Q33638083) (← links)
- The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome (Q33698398) (← links)
- Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma (Q33823270) (← links)
- Peptide-guided targeting of GPR55 for anti-cancer therapy. (Q36234465) (← links)
- Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment (Q37138590) (← links)
- Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology (Q37349409) (← links)
- Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful (Q37589543) (← links)
- A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. (Q38674589) (← links)
- Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? (Q38700209) (← links)
- Cancer Immunotherapy: Whence and Whither (Q38737924) (← links)
- The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma (Q38745141) (← links)
- Immunogenomics: using genomics to personalize cancer immunotherapy. (Q38772744) (← links)
- New targeted therapies for malignant lymphoma based on molecular heterogeneity (Q38787141) (← links)
- Checkpoint inhibition and cellular immunotherapy in lymphoma (Q38787776) (← links)
- NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors. (Q38788557) (← links)
- Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors (Q38839878) (← links)
- Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies (Q38878902) (← links)
- Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. (Q38889427) (← links)
- Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance (Q39013616) (← links)
- Diffuse large B-cell lymphoma: R-CHOP failure-what to do? (Q39027800) (← links)
- Novel treatment concepts in Hodgkin lymphoma. (Q39043082) (← links)
- The landscape of new drugs in lymphoma (Q39061630) (← links)
- Treatment of Young Adults with Acute Lymphoblastic Leukemia (Q39206217) (← links)
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment (Q39280002) (← links)
- Continuing challenges and current issues in acute lymphoblastic leukemia. (Q39366299) (← links)
- Pembrolizumab (Keytruda) (Q39615516) (← links)
- Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission (Q40396529) (← links)
- Antigen-directed therapies: an effective tool in acute myeloid leukemia? (Q40590788) (← links)
- Clinical applications of genome studies (Q41692369) (← links)
- The role of novel immunotherapies in non-Hodgkin lymphoma (Q41695080) (← links)
- Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells (Q41843869) (← links)
- Antibody darts on target for acute myelogenous leukemia (Q42318343) (← links)
- Clinical trials of CAR-T cells in China (Q42654456) (← links)
- Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma (Q47218634) (← links)
- Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity (Q47381391) (← links)
- The rocky road to personalized medicine in acute myeloid leukaemia. (Q47561008) (← links)
- Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. (Q47565868) (← links)
- Treatment of renal cell carcinoma: Current status and future directions (Q47726014) (← links)
- Redirecting T cells to hematological malignancies with bispecific antibodies. (Q48339827) (← links)
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights (Q49315568) (← links)
- Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy. (Q49356636) (← links)
- Clonal evolution in leukemia (Q49557852) (← links)
- Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. (Q49897464) (← links)